好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Clinical Features and Outcomes of Autoimmune Neuromuscular Hyperexcitability Spectrum Disorders
Autoimmune Neurology
P4 - Poster Session 4 (5:00 PM-6:00 PM)
8-012

Identify the clinical traits, neurophysiological features, and outcomes of autoimmune neuromuscular hyperexcitability spectrum disorders (ANHSD).

ANHSD encompass immune-mediated conditions marked by excessive excitability of nerve or muscle membranes, leading to potentially debilitating symptoms. Early identification of these syndromes can provide opportunities for treatment and minimize symptom burden and progression.

Retrospective review of Mayo clinic electronic medical records. 

Forty-five cases were classified as ANHSD, with the final diagnoses being immune-mediate rippling muscle disease (iRMD, 16/45; 36%), immunotherapy responsive cramp fasciculation syndrome (14/45; 31%), Isaac syndrome (5/45; 11%), Morvan syndrome (8/45; 18%), and peripheral nerve hyperexcitability with encephalitis/seizures not meeting Morvan syndrome criteria (2/45; 4%). In comparison to non-immune mediated peripheral nerve hyperexcitability (n=62), immune-mediated nerve hyperexcitability cases were associated with the presence of co-existing central nervous system involvement (p=0.03) or autonomic dysfunction (p=0.046). Among the ANHSD cases most (n=28; 62%) were seropositive. Ten tested positive for LGI1-IgG, eight for CASPR2-IgG, and sixteen for Cavin-4 IgG. Five patients were positive for both LGI1-IgG and CASPR2-IgG. In nine patients, hyperexcitability was suspected to be secondary to paraneoplastic autoimmunity, with thymoma, papillary thyroid cancer, breast cancer and small cell lung cancer in two patients each, with metastatic squamous cell cancer in one other.   Out of 40 patients with follow-up data, 35 received immunotherapy, one had thymectomy, and four received only symptomatic treatment. The majority (36/40; 90%) experienced either symptom improvement or stabilization.

In our study cohort, iRMD emerged as the most common ANHSD and should be contemplated especially when muscle hyperexcitability is electrically silent. However, combined frequency of various nerve hyperexcitability syndromes was higher than iRMD. Autoimmune nerve hyper-excitability cases often have multifocal neuroaxis involvement with co-existing dysautonomia, seizures or encephalopathy. The majority of cases were seropositive for neural specific antibodies, underscoring the importance of autoantibody evaluation in diagnosis of these cases.

 

Authors/Disclosures
Nimalan Harinesan, MBBS
PRESENTER
Dr. Harinesan has nothing to disclose.
Haidara Kherbek (Mayo Clinic) Haidara Kherbek has nothing to disclose.
Reghann LaFrance-Corey Miss LaFrance-Corey has nothing to disclose.
Christopher J. Klein, MD, FAAN (Mayo Clinic) Dr. Klein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NMD Pharma.
Margherita Milone, MD, FAAN (Mayo Clinic) Dr. Milone has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cartesian Therapeutics. Dr. Milone has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology Genetics, AAN. The institution of Dr. Milone has received research support from Mayo Clinic, CCaTS-CBD. The institution of Dr. Milone has received research support from Mayo Clinic, SGP Award. The institution of Dr. Milone has received research support from MDA for Care Center grant. The institution of Dr. Milone has received research support from Regenerative medicine Minnesota.
Teerin Liewluck, MD, FAAN (Department of Neurology, Mayo Clinic) Dr. Liewluck has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta Therapeutics. Dr. Liewluck has received publishing royalties from a publication relating to health care.
Lyell K. Jones, MD, FAAN (Mayo Clinic) Dr. Jones has received personal compensation in the range of $100,000-$499,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for 好色先生. Dr. Jones has received publishing royalties from a publication relating to health care. Dr. Jones has received personal compensation in the range of $10,000-$49,999 for serving as a President-Elect with 好色先生. Dr. Jones has a non-compensated relationship as a member of the AAN Board of Directors with AAN that is relevant to AAN interests or activities. Dr. Jones has a non-compensated relationship as a Chair of the Mayo Clinic ACO Board of Directors with Mayo Clinic that is relevant to AAN interests or activities.
William J. Litchy, MD, FAAN Dr. Litchy has nothing to disclose.
Anastasia Zekeridou, MD, PhD, FAAN (Neuroimmunology Laboratory, Mayo Clinic) The institution of Dr. Zekeridou has received research support from Roche/Genentech. Dr. Zekeridou has received intellectual property interests from a discovery or technology relating to health care. Dr. Zekeridou has received intellectual property interests from a discovery or technology relating to health care. Dr. Zekeridou has received intellectual property interests from a discovery or technology relating to health care. Dr. Zekeridou has received intellectual property interests from a discovery or technology relating to health care.
Sean J. Pittock, MD, FAAN (Mayo Clinic Dept of Neurology) Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arialys. The institution of Dr. Pittock has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. The institution of Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. The institution of Dr. Pittock has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech. The institution of Dr. Pittock has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion/AstraZeneka. The institution of Dr. Pittock has received research support from NIH. Dr. Pittock has received intellectual property interests from a discovery or technology relating to health care. Dr. Pittock has received intellectual property interests from a discovery or technology relating to health care. Dr. Pittock has received publishing royalties from a publication relating to health care.
Divyanshu Dubey, MD, FAAN (Mayo Clinic) The institution of Dr. Dubey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argenx. The institution of Dr. Dubey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arialys. The institution of Dr. Dubey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB . Dr. Dubey has received research support from Department of Defense . Dr. Dubey has received research support from Department of Defense . Dr. Dubey has received research support from UCB. Dr. Dubey has received research support from David J. Tomassoni ALS Research Grant Program . Dr. Dubey has received intellectual property interests from a discovery or technology relating to health care. Dr. Dubey has received intellectual property interests from a discovery or technology relating to health care. Dr. Dubey has received intellectual property interests from a discovery or technology relating to health care. Dr. Dubey has received intellectual property interests from a discovery or technology relating to health care.